With obesity affecting almost 2 billion adults worldwide, the recent introduction of GLP-1 agonists into the consumer market has been a welcome relief for many. The combination of busy lifestyles, high-calorie convenience food and a sedentary routine has seen global obesity rates more than double for adults between 1990 and 2022.
However, obesity can now be easily managed with these oral or injectable drugs which mimic the natural hormone, GLP-1, assisting with appetite suppression and increased feelings of satiety.
